Langenbruch, Lisa
Strippel, Christine
Görlich, Dennis
Elger, Christian E.
Möddel, Gabriel
Meuth, Sven G.
Kellinghaus, Christoph
Wiendl, Heinz
Kovac, Stjepana http://orcid.org/0000-0002-2500-6893
Funding for this research was provided by:
Universitätsklinikum Münster
Article History
Received: 9 February 2021
Revised: 3 May 2021
Accepted: 5 May 2021
First Online: 21 May 2021
Declarations
:
: L. Langenbruch has received honoraria for lecturing from Eisai and Biogen. C. Strippel, D. Görlich, and C. Elger have no conflicts to declare. S. Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Deutsche Multiple Sklerose Gesellschaft (DMSG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. C. Kellinghaus has received honoraria from Eisai and UCB. G. Möddel has received honoraria and travel expenses from UCB, Desitin, and Eisai. H. Wiendl has received honoraria for advisory service from Biogen GmbH Deutschland, Biogen Idec, Sanofi- Genzyme, Merck Serono, Novartis, Abbvie, Actelion, Immunic, Johnson and Johnson LTS, Merck Deutschland, Novartis Deutschland, Sanofi Deutschland, and Roche. He has received honoraria for lecturing and travel expenses from Bayer Vital GmbH, Bayer Schering AG, Biogen GmbH Deutschland, Biogen Idec, CSL Behring, EMD Serono, Fresenius Medical Care, Genzyme, Merck Serono, Omniamed, Novartis, Sanofi Aventis and Teva. His research is supported by Bayer Healthcare, Bayer Vital, Biogen GmbH Deutschland, Biogen Idec, Merck Serono, Novartis, Sanofi—Genzyme, Sanofi US, TEVA Pharma, Merck Serono, Novartis, by the Bundesministerium für Bildung und Forschung (BMBF), by the Deutsche Forschungsgesellschaft (DFG), by the Else-Kröner-Fresenius-, Fresenius- and Hertie-Stiftung, by the Nordrhein-Westfälisches Ministerium für Bildung und Forschung, by the Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Münster and the RE Children’s Foundation. S. Kovac received research funding support from Biogen and honoraria from Sanofi, Eisai and Genzyme.
: The study was approved by the local ethics committee of the University of Münster (2019-149-f-S) and performed in accordance with the Declaration of Helsinki.
: All patients gave written informed consent to participate in the study.
: Consent to publication was not needed, as individual patient data will not be reported.